While the subtypes do not perfectly reflect the clinical features, most breast cancers of the luminal subtypes are ER/PR-positive, most Her2-enriched ones have amplification of the Her2 gene, and most basal-like ones are triple negative (ER–/PR–/Her2–). This evidence concerns the gene ERBB2 and breast carcinoma.